Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy

BACKGROUND: Females with hypertrophic cardiomyopathy present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors behind these differences are unclear. We aimed to investigate sex-related differences in clinical and genetic factors affecting adverse outcomes in the Sarcomeric Human Cardiomyopathy Registry. METHODS: Cox proportional hazard models were fit with a sex interaction term to determine if significant sex differences existed in the association between risk factors and outcomes. Models were fit separately for females and males to find the sex-specific hazard ratio (HR). RESULTS: After a mean follow-up of 6.4 years, females had a higher risk of heart failure (HR, 1.51 [95% CI, 1.21–1.88]; P =0.0003) but a lower risk of atrial fibrillation (HR, 0.74 [95% CI, 0.59–0.93]; P <0.0001) and ventricular arrhythmia (HR, 0.60 [95% CI, 0.38–0.94]; P =0.027) than males. No sex difference was observed for death ( P =0.84). Sarcomere-positive males had higher heart failure (HR, 1.34 [95% CI, 1.06–1.69]) and death risks (HR, 1.48 [95% CI, 1.08–2.04]) not seen in females (HR, 0.85 [95% CI, 0.66–1.08] versus HR, 0.86 [95% CI, 0.71–1.21]). MYBPC3 variants lowered heart failure risk in females (HR, 0.56 [95% CI, 0.41–0.77]) but not in males (HR, 1.29 [95% CI, 0.99–1.67]). A sex difference appeared in moderate (4% to <6%) versus low risk (<4%) European Society of Cardiology hypertrophic cardiomyopathy risk score, with females at moderate risk more prone to ventricular arrhythmia (HR, 3.57 [95% CI, 1.70–7.49]), unobserved in males (HR, 1.13 [95% CI, 0.63–2.03]). CONCLUSIONS: We found that clinical and genetic factors contributing to adverse outcomes in hypertrophic cardiomyopathy affect females and males differently. Thus, research to inform sex-specific management of hypertrophic cardiomyopathy could improve outcomes for both sexes.